舒泰神：STSP-0902滴眼液获得I期临床研究总结报告

Core Viewpoint - The company has received the Phase I clinical study summary report for STSP-0902 eye drops, indicating positive safety and tolerability results in healthy subjects, supporting further trials in patients with neurotrophic keratitis [1] Group 1: Clinical Study Results - The drug STSP-0902 is intended for the treatment of neurotrophic keratitis [1] - The overall safety and tolerability of the drug were found to be good in both single and multiple dosing in healthy subjects, with most adverse events classified as CTCAE Grade 1 [1] - Pharmacokinetic results showed that the drug was detectable in all tear samples up to 6 hours after a single dose [1] Group 2: Future Implications - The results of the study support the initiation of further clinical trials in patients suffering from neurotrophic keratitis [1]